{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T03:45:20Z","timestamp":1775706320831,"version":"3.50.1"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,6,14]],"date-time":"2021-06-14T00:00:00Z","timestamp":1623628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,6,14]],"date-time":"2021-06-14T00:00:00Z","timestamp":1623628800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie Inc","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Dis Ther"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1007\/s40121-021-00455-1","type":"journal-article","created":{"date-parts":[[2021,6,14]],"date-time":"2021-06-14T11:03:01Z","timestamp":1623668581000},"page":"2203-2222","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Real-World Outcomes in Historically Underserved Patients with Chronic Hepatitis\u00a0C Infection Treated with Glecaprevir\/Pibrentasvir"],"prefix":"10.1007","volume":"10","clinical-trial-number":[{"clinical-trial-number":"nct03303599","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Alessio","family":"Aghemo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yves","family":"Horsmans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Bourgeois","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Bondin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Gschwantler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harald","family":"Hofer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nasser","family":"Semmo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Negro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhenzhen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Marcinak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ella","family":"Veitsman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rawi","family":"Hazzan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Konstantinos","family":"Mimidis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ioannis","family":"Goulis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nuno","family":"Marques","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Flisiak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wlodzimierz","family":"Mazur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"Roncero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fiona","family":"Marra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georges Philippe","family":"Pageaux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tarik","family":"Asselah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pietro","family":"Lampertico","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,6,14]]},"reference":[{"issue":"suppl 1","key":"455_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1111\/liv.13673","volume":"38","author":"T Asselah","year":"2018","unstructured":"Asselah T, Marcellin P, Schinazi RF. Treatment of hepatitis\u00a0C virus infection with direct-acting antiviral agents: 100% cure? Liver Int. 2018;38(suppl 1):7\u201313.","journal-title":"Liver Int"},{"key":"455_CR2","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.antiviral.2017.02.014","volume":"142","author":"G Li","year":"2017","unstructured":"Li G, De Clercq E. Current therapy for chronic hepatitis\u00a0C: the role of direct-acting antivirals. Antiviral Res. 2017;142:83\u2013122.","journal-title":"Antiviral Res"},{"key":"455_CR3","unstructured":"WHO. Global hepatitis report, 2017. World Health Organization. 2017. http:\/\/apps.who.int\/iris\/bitstream\/10665\/255016\/1\/9789241565455-eng.pdf. Accessed 10 Feb 2021."},{"key":"455_CR4","unstructured":"WHO. Guidelines for the care and treatment of persons diagnosed with chronic hepatitis\u00a0C virus infection, July 2018. 2018. https:\/\/www.who.int\/hepatitis\/publications\/hepatitis-c-guidelines-2018\/en\/. Accessed 10 Feb 2021."},{"issue":"7","key":"455_CR5","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1056\/NEJMp2002126","volume":"383","author":"GJ Dore","year":"2020","unstructured":"Dore GJ, Trooskin S. People with hepatitis\u00a0C who inject drugs\u2014underserved, not undeserving. N Engl J Med. 2020;383(7):608\u201311.","journal-title":"N Engl J Med"},{"issue":"3","key":"455_CR6","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1055\/s-0038-1666841","volume":"38","author":"JV Lazarus","year":"2018","unstructured":"Lazarus JV, Safreed-Harmon K, Thursz MR, et al. The micro-elimination approach to eliminating hepatitis\u00a0C: strategic and operational considerations. Semin Liver Dis. 2018;38(3):181\u201392.","journal-title":"Semin Liver Dis"},{"issue":"suppl 1","key":"455_CR7","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1111\/liv.13626","volume":"38","author":"S Pol","year":"2018","unstructured":"Pol S, Parlati L. Treatment of hepatitis\u00a0C: the use of the new pangenotypic direct-acting antivirals in \u201cspecial populations.\u201d Liver Int. 2018;38(suppl 1):28\u201333.","journal-title":"Liver Int"},{"key":"455_CR8","unstructured":"AASLD-IDSA. Key populations: identification and management of HCV in people who inject drugs (updated November 6, 2019). https:\/\/www.hcvguidelines.org\/unique-populations\/pwid. Accessed 10 Feb 2021."},{"issue":"5","key":"455_CR9","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1002\/hep.26431","volume":"58","author":"NK Martin","year":"2013","unstructured":"Martin NK, Vickerman P, Grebely J, Hellard M, Hutchinson SJ, Lima VD, et al. Hepatitis\u00a0C virus treatment for prevention among people who inject drugs: modeling treatment scale-up in the age of direct-acting antivirals. Hepatology. 2013;58(5):1598\u2013609.","journal-title":"Hepatology"},{"issue":"2","key":"455_CR10","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/S1473-3099(17)30676-X","volume":"18","author":"A Zelenev","year":"2018","unstructured":"Zelenev A, Mazhnaya A, Basu S, Altice FL. Hepatitis\u00a0C virus treatment as prevention in an extended network of people who inject drugs in the USA: a modelling study. Lancet Infect Dis. 2018;18(2):215\u201324.","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"455_CR11","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1186\/s12889-019-6847-5","volume":"19","author":"BL Edmunds","year":"2019","unstructured":"Edmunds BL, Miller ER, Tsourtos G. The distribution and socioeconomic burden of Hepatitis\u00a0C virus in South Australia: a cross-sectional study 2010\u20132016. BMC Public Health. 2019;19(1):527.","journal-title":"BMC Public Health"},{"issue":"2","key":"455_CR12","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1353\/hpu.2014.0096","volume":"25","author":"RJ Roose","year":"2014","unstructured":"Roose RJ, Cockerham-Colas L, Soloway I, Batchelder A, Litwin AH. Reducing barriers to hepatitis\u00a0C treatment among drug users: an integrated hepatitis\u00a0C peer education and support program. J Health Care Poor Underserved. 2014;25(2):652\u201362.","journal-title":"J Health Care Poor Underserved"},{"key":"455_CR13","unstructured":"AASLD-IDSA. Recommendations for testing, managing, and treating hepatitis\u00a0C. http:\/\/www.hcvguidelines.org. Accessed 10 Feb 2021."},{"issue":"2","key":"455_CR14","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.jhep.2018.03.026","volume":"69","author":"EASL","year":"2018","unstructured":"EASL. EASL recommendations on treatment of hepatitis\u00a0C 2018. J Hepatol. 2018;69(2):461\u2013511.","journal-title":"J Hepatol"},{"key":"455_CR15","unstructured":"Maviret EU. Maviret. 2020. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/maviret-epar-product-information_en.pdf. Accessed 20 Dec 2020."},{"issue":"3","key":"455_CR16","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.cgh.2017.09.027","volume":"16","author":"T Asselah","year":"2018","unstructured":"Asselah T, Kowdley KV, Zadeikis N, et al. Efficacy of glecaprevir\/pibrentasvir for 8 or 12 weeks in patients with hepatitis\u00a0C virus genotype 2, 4, 5, or 6 infection without cirrhosis. Clin Gastroenterol Hepatol. 2018;16(3):417\u201326.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"455_CR17","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1056\/NEJMoa1702417","volume":"378","author":"S Zeuzem","year":"2018","unstructured":"Zeuzem S, Foster GR, Wang S, et al. Glecaprevir-pibrentasvir for 8 or 12 weeks in HCV genotype 1 or 3 infection. N Engl J Med. 2018;378(4):354\u201369.","journal-title":"N Engl J Med"},{"issue":"3","key":"455_CR18","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.jhep.2019.10.020","volume":"72","author":"RS Brown Jr","year":"2020","unstructured":"Brown RS Jr, Buti M, Rodrigues L, et al. Glecaprevir\/pibrentasvir for 8 weeks in treatment-naive patients with chronic HCV genotypes 1\u20136 and compensated cirrhosis: the EXPEDITION-8 trial. J Hepatol. 2020;72(3):441\u20139.","journal-title":"J Hepatol"},{"issue":"8","key":"455_CR19","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1111\/apt.15222","volume":"49","author":"T Berg","year":"2019","unstructured":"Berg T, Naumann U, Stoehr A, et al. Real-world effectiveness and safety of glecaprevir\/pibrentasvir for the treatment of chronic hepatitis\u00a0C infection: data from the German Hepatitis\u00a0C-Registry. Aliment Pharmacol Ther. 2019;49(8):1052\u20139.","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"455_CR20","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.jhep.2018.11.011","volume":"70","author":"R D'Ambrosio","year":"2019","unstructured":"D\u2019Ambrosio R, Pasulo L, Puoti M, et al. Real-world effectiveness and safety of glecaprevir\/pibrentasvir in 723 patients with chronic hepatitis\u00a0C. J Hepatol. 2019;70(3):379\u201387.","journal-title":"J Hepatol"},{"issue":"11","key":"455_CR21","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1136\/gutjnl-2015-310421","volume":"64","author":"F Zoulim","year":"2015","unstructured":"Zoulim F, Liang TJ, Gerbes AL, et al. Hepatitis\u00a0C virus treatment in the real world: optimising treatment and access to therapies. Gut. 2015;64(11):1824\u201333.","journal-title":"Gut"},{"issue":"1","key":"455_CR22","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1186\/s12879-019-4315-6","volume":"19","author":"CL Cooper","year":"2019","unstructured":"Cooper CL, Galanakis C, Donelle J, et al. HCV-infected individuals have higher prevalence of comorbidity and multimorbidity: a retrospective cohort study. BMC Infect Dis. 2019;19(1):712.","journal-title":"BMC Infect Dis"},{"issue":"suppl 1","key":"455_CR23","first-page":"A417","volume":"68","author":"P Belperio","year":"2018","unstructured":"Belperio P, Shahoumian T, Loomis T, Mole L, Backus L. Real-world effectiveness of glecaprevir\/pibrentasvir in 1941 patients with hepatitis\u00a0C genotypes 1 through 4. Hepatology. 2018;68(suppl 1):A417\u2013A418 (abstract 703).","journal-title":"Hepatology"},{"issue":"suppl 1","key":"455_CR24","first-page":"A957","volume":"70","author":"F Marra","year":"2019","unstructured":"Marra F, Boyle A, McDonald N, et al. 8 weeks of glecaprevir\/pibrentasvir is effective and well tolerated in non-GT3 HCV patients with cirrhosis. Hepatology. 2019;70(suppl 1):A957\u2013A958 (abstract 1588).","journal-title":"Hepatology"},{"issue":"10","key":"455_CR25","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.1111\/liv.14170","volume":"39","author":"M Persico","year":"2019","unstructured":"Persico M, Aglitti A, Milella M, et al. Real-life glecaprevir\/pibrentasvir in a large cohort of patients with hepatitis\u00a0C virus infection: the MISTRAL study. Liver Int. 2019;39(10):1852\u20139.","journal-title":"Liver Int"},{"key":"455_CR26","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.1007\/s12325-020-01301-5","volume":"37","author":"F Steve","year":"2020","unstructured":"Steve F, Jens K, Steven M, et al. Effectiveness of 8-week glecaprevir\/pibrentasvir for treatment naive, compensated cirrhotic patients with chronic hepatitis\u00a0C infection. Adv Ther. 2020;37:2267\u201374.","journal-title":"Adv Ther"},{"issue":"suppl 1","key":"455_CR27","first-page":"A94","volume":"68","author":"P Cacoub","year":"2018","unstructured":"Cacoub P, Bondin MI, Hayes O, Pinsky B, Negro F. Quality of life in patients with psychiatric disorders: pooled analysis from glecaprevir\/pibrentasvir registrational studies. Heptology. 2018;68(suppl 1):A94\u2013A95 (abstract 150).","journal-title":"Heptology"},{"issue":"11","key":"455_CR28","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1111\/j.1365-2036.2006.02934.x","volume":"23","author":"JJ Gutteling","year":"2006","unstructured":"Gutteling JJ, de Man RA, van der Plas SM, Schalm SW, Busschbach JJ, Darlington AS. Determinants of quality of life in chronic liver patients. Aliment Pharmacol Ther. 2006;23(11):1629\u201335.","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"455_CR29","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1097\/PHM.0000000000000050","volume":"93","author":"A Loria","year":"2014","unstructured":"Loria A, Doyle K, Weinstein AA, et al. Multiple factors predict physical performance in people with chronic liver disease. Am J Phys Med Rehabil. 2014;93(6):470\u20136.","journal-title":"Am J Phys Med Rehabil"},{"issue":"2","key":"455_CR30","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/S0033-3182(10)70676-9","volume":"51","author":"JJ Gutteling","year":"2010","unstructured":"Gutteling JJ, Duivenvoorden HJ, Busschbach JJ, de Man RA, Darlington AS. Psychological determinants of health-related quality of life in patients with chronic liver disease. Psychosomatics. 2010;51(2):157\u201365.","journal-title":"Psychosomatics"},{"issue":"6","key":"455_CR31","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1038\/ajg.2016.99","volume":"111","author":"ZM Younossi","year":"2016","unstructured":"Younossi ZM, Stepanova M, Henry L, Nader F, Hunt S. An in-depth analysis of patient-reported outcomes in patients with chronic hepatitis\u00a0C treated with different anti-viral regimens. Am J Gastroenterol. 2016;111(6):808\u201316.","journal-title":"Am J Gastroenterol"},{"issue":"7","key":"455_CR32","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1093\/infdis\/jix681","volume":"217","author":"M Stepanova","year":"2017","unstructured":"Stepanova M, Thompson A, Doyle J, Younossi I, de Avila L, Younossi ZM. Hepatitis C virus\u2013infected patients receiving opioid substitution therapy experience improvement in patient-reported outcomes following treatment with interferon-free regimens. J Infect Dis. 2017;217(7):1033\u201343.","journal-title":"J Infect Dis"},{"key":"455_CR33","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/1477-7525-12-90","volume":"12","author":"K Rosa","year":"2014","unstructured":"Rosa K, Fu M, Gilles L, et al. Validation of the Fatigue Severity Scale in chronic hepatitis\u00a0C. Health Qual Life Outcomes. 2014;12:90.","journal-title":"Health Qual Life Outcomes"},{"issue":"6","key":"455_CR34","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","volume":"30","author":"JE Ware Jr","year":"1992","unstructured":"Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30(6):473\u201383.","journal-title":"Med Care"},{"issue":"4","key":"455_CR35","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1185\/030079907X178757","volume":"23","author":"JB Bjorner","year":"2007","unstructured":"Bjorner JB, Wallenstein GV, Martin MC, et al. Interpreting score differences in the SF-36 Vitality scale: using clinical conditions and functional outcomes to define the minimally important difference. Curr Med Res Opin. 2007;23(4):731\u20139.","journal-title":"Curr Med Res Opin"},{"key":"455_CR36","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/1477-7525-11-82","volume":"11","author":"V Strand","year":"2013","unstructured":"Strand V, Fiorentino D, Hu C, Day RM, Stevens RM, Papp KA. Improvements in patient-reported outcomes with apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of moderate to severe psoriasis: results from a phase IIb randomized, controlled study. Health Qual Life Outcomes. 2013;11:82.","journal-title":"Health Qual Life Outcomes"},{"issue":"suppl 1","key":"455_CR37","first-page":"A917","volume":"70","author":"H Wedemeyer","year":"2019","unstructured":"Wedemeyer H, Erren P, Naumann U, et al. Glecaprevir\/pibrentasvir is effective and well tolerated in hepatitis c patients with cirrhosis: real-world experience from the German Hepatitis\u00a0C-Registry. Hepatology. 2019;70(suppl 1):A917\u2013A918 (abstract 1525).","journal-title":"Hepatology"},{"issue":"3","key":"455_CR38","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1111\/liv.14324","volume":"40","author":"H Razavi","year":"2020","unstructured":"Razavi H, Sanchez Gonzalez Y, Yuen C, Cornberg M. Global timing of hepatitis\u00a0C virus elimination in high-income countries. Liver Int. 2020;40(3):522\u20139.","journal-title":"Liver Int"},{"issue":"suppl 1","key":"455_CR39","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1111\/jvh.12249","volume":"21","author":"H Wedemeyer","year":"2014","unstructured":"Wedemeyer H, Duberg AS, Buti M, et al. Strategies to manage hepatitis\u00a0C virus (HCV) disease burden. J Viral Hepatitis. 2014;21(suppl 1):60\u201389.","journal-title":"J Viral Hepatitis"},{"key":"455_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2147\/HMER.S187133","volume":"11","author":"C Roncero","year":"2019","unstructured":"Roncero C, Ryan P, Littlewood R, et al. Practical steps to improve chronic hepatitis\u00a0C treatment in people with opioid use disorder. Hepatic Med Evid Res. 2019;11:1\u201311.","journal-title":"Hepatic Med Evid Res"},{"issue":"suppl 2","key":"455_CR41","doi-asserted-by":"publisher","first-page":"S39","DOI":"10.1093\/cid\/cit296","volume":"57","author":"NK Martin","year":"2013","unstructured":"Martin NK, Hickman M, Hutchinson SJ, Goldberg DJ, Vickerman P. Combination interventions to prevent HCV transmission among people who inject drugs: modeling the impact of antiviral treatment, needle and syringe programs, and opiate substitution therapy. Clin Infect Dis. 2013;57(suppl 2):S39\u201345.","journal-title":"Clin Infect Dis"},{"issue":"5","key":"455_CR42","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1097\/COH.0000000000000179","volume":"10","author":"NK Martin","year":"2015","unstructured":"Martin NK, Vickerman P, Dore GJ, Hickman M. The hepatitis\u00a0C virus epidemics in key populations (including people who inject drugs, prisoners and MSM): the use of direct-acting antivirals as treatment for prevention. Curr Opin HIV AIDS. 2015;10(5):374\u201380.","journal-title":"Curr Opin HIV AIDS"},{"issue":"suppl 1","key":"455_CR43","first-page":"954A","volume":"70","author":"P Lampertico","year":"2019","unstructured":"Lampertico P, Peck-Radosavljevic M, Bondin M, et al. Addressing barriers to hepatitis c virus (HCV) elimination: real-world outcomes in historically underserved patients with chronic HCV infection treated with glecaprevir\/pibrentasvir. Hepatology. 2019;70(suppl 1):954A (abstract 1583).","journal-title":"Hepatology"},{"key":"455_CR44","first-page":"47","volume":"21","author":"RF Palma-\u00c1lvarez","year":"2019","unstructured":"Palma-\u00c1lvarez RF, Ros-Cucurull E, Grau-L\u00f3pez L, et al. Difficulties in initiating hepatitis\u00a0C treatment in patients with opioid usdisorder: patient\u2019s perspective. Heroin Addict Relat Clin Probl. 2019;21:47\u201351.","journal-title":"Heroin Addict Relat Clin Probl"},{"issue":"3","key":"455_CR45","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/j.jhep.2017.10.010","volume":"68","author":"H Fraser","year":"2018","unstructured":"Fraser H, Martin NK, Brummer-Korvenkontio H, et al. Model projections on the impact of HCV treatment in the prevention of HCV transmission among people who inject drugs in Europe. J Hepatol. 2018;68(3):402\u201311.","journal-title":"J Hepatol"},{"key":"455_CR46","unstructured":"WHO. Progress report on access to hepatitis\u00a0C treatment 2018. https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/260445\/WHO-CDS-HIV-18.4-eng.pdf;jsessionid=AC7402ADBBC3BA2404E5DF4768BE7F9B?sequence=1. Accessed 10 Feb 2021."},{"issue":"3","key":"455_CR47","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.bjid.2019.04.010","volume":"23","author":"AS Benzaken","year":"2019","unstructured":"Benzaken AS, Girade R, Catapan E, et al. Hepatitis\u00a0C disease burden and strategies for elimination by 2030 in Brazil. A mathematical modeling approach. Braz J Infect Dis. 2019;23(3):182\u201390.","journal-title":"Braz J Infect Dis"},{"issue":"10","key":"455_CR48","first-page":"731","volume":"111","author":"JL Calleja Panero","year":"2019","unstructured":"Calleja Panero JL, Lens Garcia S, Fernandez Bermejo M, Crespo J. Definition of the profiles of hepatitis\u00a0C virus patients based on the identification of risky practices in Spain. Rev Esp Enferm Dig. 2019;111(10):731\u20137.","journal-title":"Rev Esp Enferm Dig"},{"issue":"6","key":"455_CR49","doi-asserted-by":"publisher","first-page":"e026726","DOI":"10.1136\/bmjopen-2018-026726","volume":"9","author":"Q Chen","year":"2019","unstructured":"Chen Q, Ayer T, Bethea E, et al. Changes in hepatitis\u00a0C burden and treatment trends in Europe during the era of direct-acting antivirals: a modelling study. BMJ Open. 2019;9(6):e026726.","journal-title":"BMJ Open"},{"issue":"9","key":"455_CR50","doi-asserted-by":"publisher","first-page":"1900","DOI":"10.1093\/cid\/ciz546","volume":"70","author":"AJ Wade","year":"2020","unstructured":"Wade AJ, Doyle JS, Gane E, et al. Outcomes of treatment for hepatitis C in primary care, compared to hospital-based care: a randomized, controlled trial in people who inject drugs. Clin Infect Dis. 2020;70(9):1900\u20136.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"455_CR51","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/S2468-1253(18)30341-8","volume":"4","author":"T Asselah","year":"2019","unstructured":"Asselah T, Lee SS, Yao BB, et al. Efficacy and safety of glecaprevir\/pibrentasvir in patients with chronic hepatitis\u00a0C virus genotype 5 or 6 infection (ENDURANCE-5,6): an open-label, multicentre, phase 3b trial. Lancet Gastroenterol Hepatol. 2019;4(1):45\u201351.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"4","key":"455_CR52","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1016\/j.jhep.2017.11.037","volume":"68","author":"T Asselah","year":"2018","unstructured":"Asselah T, Hassanein T, Waked I, Mansouri A, Dusheiko G, Gane E. Eliminating hepatitis\u00a0C within low-income countries\u2014the need to cure genotypes 4, 5, 6. J Hepatol. 2018;68(4):814\u201326.","journal-title":"J Hepatol"},{"issue":"9","key":"455_CR53","doi-asserted-by":"publisher","first-page":"594","DOI":"10.7326\/M18-1715","volume":"170","author":"MJ Akiyama","year":"2019","unstructured":"Akiyama MJ, Norton BL, Arnsten JH, Agyemang L, Heo M, Litwin AH. Intensive models of hepatitis\u00a0C care for people who inject drugs receiving opioid agonist therapy: a randomized controlled trial. Ann Intern Med. 2019;170(9):594\u2013603.","journal-title":"Ann Intern Med"},{"issue":"suppl 1","key":"455_CR54","first-page":"2","volume":"68","author":"JJ Feld","year":"2018","unstructured":"Feld JJ, Sanchez Gonzalez Y, Pires AG, Ethgen O. Clinical benefits, economic savings and faster time to HCV elimination with a simplified 8-week treatment and monitoring program in chronic F0\u2013F3 na\u00efve patients in the US. Hepatology. 2018;68(suppl 1):2 (abstract 688).","journal-title":"Hepatology"},{"issue":"12","key":"455_CR55","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1111\/jvh.12580","volume":"23","author":"EJ Aspinall","year":"2016","unstructured":"Aspinall EJ, Mitchell W, Schofield J, et al. A matched comparison study of hepatitis\u00a0C treatment outcomes in the prison and community setting, and an analysis of the impact of prison release or transfer during therapy. J Viral Hepat. 2016;23(12):1009\u201316.","journal-title":"J Viral Hepat"},{"issue":"Suppl 10","key":"455_CR56","first-page":"19","volume":"89","author":"M Galli","year":"2018","unstructured":"Galli M, Ridolfo A, van denBogaart L, Negri C, Giacomelli A. HCV and immigration in Italy. Acta Biomed. 2018;89(Suppl 10):19\u201332.","journal-title":"Acta Biomed"},{"issue":"6","key":"455_CR57","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1053\/j.gastro.2015.08.035","volume":"149","author":"F Negro","year":"2015","unstructured":"Negro F, Forton D, Crax\u00ec A, Sulkowski MS, Feld JJ, Manns MP. Extrahepatic morbidity and mortality of chronic hepatitis\u00a0C. Gastroenterology. 2015;149(6):1345\u201360.","journal-title":"Gastroenterology"}],"updated-by":[{"DOI":"10.1007\/s40121-021-00529-0","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2021,9,16]],"date-time":"2021-09-16T00:00:00Z","timestamp":1631750400000}}],"container-title":["Infectious Diseases and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-021-00455-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40121-021-00455-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-021-00455-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,3]],"date-time":"2023-02-03T23:21:11Z","timestamp":1675466471000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40121-021-00455-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,14]]},"references-count":57,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["455"],"URL":"https:\/\/doi.org\/10.1007\/s40121-021-00455-1","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s40121-021-00529-0","asserted-by":"object"}]},"ISSN":["2193-8229","2193-6382"],"issn-type":[{"value":"2193-8229","type":"print"},{"value":"2193-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,14]]},"assertion":[{"value":"5 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2021","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s40121-021-00529-0","URL":"https:\/\/doi.org\/10.1007\/s40121-021-00529-0","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}}]}}